Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ib-Meca SCHEMBL12265127 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29572081 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29634441 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL448115 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL10089200 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29384499 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL10089244 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL8922766 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL20905217 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29762168 | 0.94 | ADORA3 (0.89) | ADORA3ADORA1CYP3A4MAPK1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-04-15 | — | — | US | claimed |
| US-10620222-B2 | Electrified compositions for determining the risk of developing adolescent idiopathic scoliosis through the use of GI protein receptor | CHU SAINTE-JUSTINE (CA) | 2020-04-14 | — | — | US | claimed |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2020-03-26 | — | — | US | claimed |
| US-10265337-B2 | Use of A3 adenosine receptor agonist in osteoarthritis treatment | CAN-FITE BIOPHARMA LTD. (IL) | 2019-04-23 | — | — | US | claimed |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-04-18 | — | — | US | claimed |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | claimed |
| US-20170087158-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2017-03-30 | — | — | US | claimed |
| US-20160263142-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | CAN-FITE BIOPHARMA LTD. (IL) | 2016-09-15 | — | — | US | claimed |
| US-9387220-B2 | Method for inducing hepatocyte proliferation and uses thereof | CAN-FITE BIOPHARMA LTD. (IL) | 2016-07-12 | — | — | US | claimed |
| US-20160146839-A1 | METHODS FOR THE CLASSIFICATION AND DIAGNOSIS OF SCOLIOSIS THROUGH THE USE OF GI PROTEIN RECEPTOR | CHU SAINTE-JUSTINE (CA) | 2016-05-26 | — | — | US | claimed |
| EP-2227234-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | Can-Fite Biopharma Ltd. (IL) | 2010-09-15 | — | — | EP | claimed |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2010-05-06 | — | — | US | claimed |
| WO-2010040234-A1 | METHODS FOR THE CLASSIFICATION AND DIAGNOSIS OF SCOLIOSIS | CHU SAINTE-JUSTINE (CA) | 2010-04-15 | — | — | WO | claimed |
| US-7589075-B2 | Use of an adenosine A3 receptor agonist for inhibition of viral replication | CAN-FITE BIOPHARMA LTD. (IL) | 2009-09-15 | — | — | US | claimed |
| WO-2009050707-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN-FITE BIOPHARMA LTD. (IL) | 2009-04-23 | — | — | WO | claimed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| EP-1365776-B1 | USE OF AN ADENOSINE A3 RECEPTOR AGONIST FOR INHIBITION OF VIRAL REPLICATION | CAN FITE BIOPHARMA LTD (IL) | 2005-04-13 | — | — | EP | claimed |
| US-20040106572-A1 | Use of an adenosine a3 receptor agonist for inhibition of viral replication | CAN-FITE BIOPHARMA LTD. (IL) | 2004-06-03 | — | — | US | claimed |
| US-20020115635-A1 | Modulation of GSK-3beta activity and its different uses | CAN-FITE TECHNOLOGIES LTD. (IL) | 2002-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106572-A1 | Use of an adenosine a3 receptor agonist for inhibition of viral replication | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885CYP3A4 1255/4885 |
| US-20170087158-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | ADORA3 2713/4885ADORA1 2816/4885CYP3A4 2434/4885 |
| US-20160263142-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885CYP3A4 2407/4885 |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | ADORA3 4004/4885ADORA1 4317/4885CYP3A4 3031/4885 |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ADORA1 4/4885CYP3A4 1273/4885 |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | ADORA3 4004/4885ADORA1 4317/4885CYP3A4 3031/4885 |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA3 32/4885ADORA1 39/4885CYP3A4 4766/4885 |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ADORA1 4/4885CYP3A4 1273/4885 |
| US-10265337-B2 | Use of A3 adenosine receptor agonist in osteoarthritis treatment | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885CYP3A4 2407/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA1 3/4885CYP3A4 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.